Suchergebnisse - "Acrylamides"

Microfluidic-assisted preparation of ARV 825 and Osimertinib loaded liposomal formulation as a potential system for colorectal cancer therapy.

Autoren: Patel A Tiboni M Casettari L et al.

Quelle: International journal of pharmaceutics [Int J Pharm] 2025 Dec 25; Vol. 686, pp. 126358. Date of Electronic Publication: 2025 Nov 04.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3476 (Electronic) Linking ISSN: 03785173 NLM ISO Abbreviation: Int J Pharm Subsets: MEDLINE

MeSH-Schlagworte: Acrylamides*/administration & dosage , Acrylamides*/pharmacology , Acrylamides*/chemistry , Aniline Compounds*/administration & dosage , Aniline Compounds*/pharmacology , Aniline Compounds*/chemistry , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/pathology , Antineoplastic Agents*/administration & dosage , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/pharmacology, Liposomes ; Humans ; Cell Cycle Proteins/metabolism ; Cell Cycle Proteins/antagonists & inhibitors ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Cell Line, Tumor ; Transcription Factors/metabolism ; Transcription Factors/antagonists & inhibitors ; Drug Compounding/methods ; Apoptosis/drug effects ; Particle Size ; Cell Survival/drug effects ; Microfluidics/methods ; Drug Stability ; Drug Liberation ; Bromodomain Containing Proteins ; Indoles ; Pyrimidines

Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer.

Autoren: Yang H Hu L Su Z et al.

Quelle: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2025 Dec 10; Vol. 388 (Pt 1), pp. 114345. Date of Electronic Publication: 2025 Oct 21.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Proto-Oncogene Proteins p21(ras)*/genetics , Proto-Oncogene Proteins p21(ras)*/antagonists & inhibitors , Antineoplastic Agents*/administration & dosage , Antineoplastic Agents*/therapeutic use , Acrylamides*/administration & dosage , Acrylamides*/therapeutic use , Single-Domain Antibodies*/administration & dosage , Nanoparticles*/administration & dosage, Animals ; Humans ; Cell Line, Tumor ; ErbB Receptors/metabolism ; Mutation ; Mice, Nude ; Female ; Mice ; Mice, Inbred BALB C ; B7-H1 Antigen/antagonists & inhibitors

Activation of autophagy as a strategy to overcome Osimertinib-resistance in non-small cell lung cancer.

Autoren: Jang YW Bae WY Ji SM et al.

Quelle: European journal of pharmacology [Eur J Pharmacol] 2025 Dec 05; Vol. 1008, pp. 178371. Date of Electronic Publication: 2025 Nov 13.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0712 (Electronic) Linking ISSN: 00142999 NLM ISO Abbreviation: Eur J Pharmacol Subsets: MEDLINE

MeSH-Schlagworte: Autophagy*/drug effects , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/drug therapy , Aniline Compounds*/pharmacology , Aniline Compounds*/therapeutic use , Acrylamides*/pharmacology , Acrylamides*/therapeutic use , Drug Resistance, Neoplasm*/drug effects , Lung Neoplasms*/pathology , Lung Neoplasms*/drug therapy , Antineoplastic Agents*/pharmacology, Humans ; Animals ; Mice ; Cell Line, Tumor ; Xenograft Model Antitumor Assays ; Sirolimus/pharmacology ; Protein Kinase Inhibitors/pharmacology ; Indoles ; Pyrimidines

A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.

Autoren: Shi Y Lv D Feng W et al.

Quelle: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2025 Dec 02; Vol. 10 (1), pp. 393. Date of Electronic Publication: 2025 Dec 02.

Publikationsart: Journal Article; Multicenter Study

Info zur Zeitschrift: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Aniline Compounds*/administration & dosage , Acrylamides*/administration & dosage , Acrylamides*/therapeutic use , Lung Neoplasms*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology, Humans ; ErbB Receptors/genetics ; Female ; Male ; Middle Aged ; Aged ; Mutation ; Adult ; Prospective Studies ; Aged, 80 and over ; High-Throughput Nucleotide Sequencing ; Treatment Failure ; Indoles ; Pyrimidines

Efficacy of Almonertinib Versus Osimertinib as the First-Line Treatment for Non-Small Cell Lung Cancer With EGFR L858R Mutation and Prognostic Analysis: A Retrospective Comparative Cohort Study.

Autoren: Yao X Li R Dong X et al.

Quelle: Cancer medicine [Cancer Med] 2025 Dec; Vol. 14 (23), pp. e71422.

Publikationsart: Journal Article; Comparative Study

Info zur Zeitschrift: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/mortality , Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Lung Neoplasms*/mortality , Aniline Compounds*/therapeutic use , Aniline Compounds*/adverse effects , Acrylamides*/therapeutic use , Acrylamides*/adverse effects , Mutation* , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/adverse effects, Humans ; Male ; Female ; ErbB Receptors/genetics ; Aged ; Middle Aged ; Retrospective Studies ; Prognosis ; Adult ; Aged, 80 and over ; Progression-Free Survival ; Treatment Outcome ; Indoles ; Pyrimidines

Ion mobility-mass spectrometry of palytoxin-like compounds produced by Ostreopsis cf. ovata.

Autoren: Medina-Pérez NI Peralta-Moreno MN Rubio-Martinez J et al.

Quelle: Analytical and bioanalytical chemistry [Anal Bioanal Chem] 2025 Dec; Vol. 417 (29), pp. 6665-6677. Date of Electronic Publication: 2025 Oct 16.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101134327 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-2650 (Electronic) Linking ISSN: 16182642 NLM ISO Abbreviation: Anal Bioanal Chem Subsets: MEDLINE

MeSH-Schlagworte: Ion Mobility Spectrometry*/methods , Acrylamides*/chemistry , Acrylamides*/analysis , Mass Spectrometry*/methods , Dinoflagellida*/chemistry , Marine Toxins*/chemistry, Cnidarian Venoms ; Molecular Dynamics Simulation ; Polyether Toxins

Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational study.

Autoren: Zhong H Jiang S Yao W et al.

Quelle: Future oncology (London, England) [Future Oncol] 2025 Dec; Vol. 21 (28), pp. 3639-3648. Date of Electronic Publication: 2025 Oct 30.

Publikationsart: Journal Article; Multicenter Study; Observational Study

Info zur Zeitschrift: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Acrylamides*/adverse effects , Acrylamides*/therapeutic use , Acrylamides*/administration & dosage , Aniline Compounds*/adverse effects , Aniline Compounds*/administration & dosage , Aniline Compounds*/therapeutic use , Protein Kinase Inhibitors*/adverse effects , Antineoplastic Agents*/adverse effects , Antineoplastic Agents*/therapeutic use, Humans ; Female ; Male ; Aged ; Prospective Studies ; Middle Aged ; Aged, 80 and over ; China/epidemiology ; Adult ; East Asian People ; Indoles ; Pyrimidines

A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2).

Autoren: Morinaga D Furuta M Morita S et al.

Körperschaften: Morinaga D Furuta M Morita S et al.

Quelle: Clinical lung cancer [Clin Lung Cancer] 2025 Dec; Vol. 26 (8), pp. 611-616. Date of Electronic Publication: 2025 Aug 26.

Publikationsart: Journal Article; Clinical Trial, Phase II

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/pathology , Aniline Compounds*/administration & dosage , Aniline Compounds*/therapeutic use , Acrylamides*/administration & dosage , Acrylamides*/therapeutic use , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Mutation*, Humans ; Pemetrexed/administration & dosage ; Pemetrexed/therapeutic use ; ErbB Receptors/genetics ; Female ; Male ; Middle Aged ; Aged ; Adult ; Platinum/administration & dosage ; Clinical Trials, Phase II as Topic ; Indoles ; Pyrimidines

Targeting PDK4 to mitigate osimertinib-induced cardiotoxicity: Insights into mitochondria-endoplasmic reticulum crosstalk and necroptosis.

Autoren: Deng J Wang D Jiang K et al.

Quelle: Free radical biology & medicine [Free Radic Biol Med] 2025 Dec 01; Vol. 240, pp. 267-283. Date of Electronic Publication: 2025 Aug 09.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Country of Publication: United States NLM ID: 8709159 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4596 (Electronic) Linking ISSN: 08915849 NLM ISO Abbreviation: Free Radic Biol Med Subsets: MEDLINE

MeSH-Schlagworte: Acrylamides*/adverse effects , Acrylamides*/toxicity , Necroptosis*/drug effects , Myocytes, Cardiac*/drug effects , Myocytes, Cardiac*/metabolism , Myocytes, Cardiac*/pathology , Aniline Compounds*/adverse effects , Aniline Compounds*/toxicity , Cardiotoxicity*/pathology , Cardiotoxicity*/etiology , Cardiotoxicity*/metabolism , Pyruvate Dehydrogenase Acetyl-Transferring Kinase*/genetics , Pyruvate Dehydrogenase Acetyl-Transferring Kinase*/metabolism , Pyruvate Dehydrogenase Acetyl-Transferring Kinase*/antagonists & inhibitors , Endoplasmic Reticulum*/drug effects , Endoplasmic Reticulum*/metabolism , Mitochondria*/drug effects , Mitochondria*/metabolism, Animals ; Mice ; Rats ; Humans ; Calcium/metabolism ; Male ; Cell Line ; Indoles ; Pyrimidines

Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation.

Autoren: Su L Zhang X Li M et al.

Quelle: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2025 Dec; Vol. 25 (10), pp. 1437-1444. Date of Electronic Publication: 2025 Jun 17.

Publikationsart: Journal Article; Comparative Study

Info zur Zeitschrift: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8379 (Electronic) Linking ISSN: 14737167 NLM ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Subsets: MEDLINE

MeSH-Schlagworte: Aniline Compounds*/economics , Aniline Compounds*/administration & dosage , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/economics , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/pathology , Quinazolinones*/economics , Quinazolinones*/administration & dosage , Acrylamides*/economics , Acrylamides*/administration & dosage , Lung Neoplasms*/drug therapy , Lung Neoplasms*/economics , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology, Humans ; Cost-Benefit Analysis ; Mutation ; ErbB Receptors/genetics ; Quality-Adjusted Life Years ; China ; Antineoplastic Agents/economics ; Antineoplastic Agents/administration & dosage ; Network Meta-Analysis as Topic ; Survival Analysis ; Indoles ; Pyrimidines

Osimertinib Cost Minimization in Non-Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination with Cobicistat.

Autoren: Westra N Kruithof PD Croes S et al.

Quelle: Journal of clinical pharmacology [J Clin Pharmacol] 2025 Dec; Vol. 65 (12), pp. 1687-1698. Date of Electronic Publication: 2025 Jul 31.

Publikationsart: Journal Article; Randomized Controlled Trial

Info zur Zeitschrift: Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/economics , Acrylamides*/pharmacokinetics , Acrylamides*/administration & dosage , Acrylamides*/economics , Aniline Compounds*/pharmacokinetics , Aniline Compounds*/administration & dosage , Aniline Compounds*/economics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/economics , Carbamates*/administration & dosage , Carbamates*/pharmacokinetics , Carbamates*/economics , Antineoplastic Agents*/pharmacokinetics , Antineoplastic Agents*/administration & dosage , Antineoplastic Agents*/economics , Antineoplastic Combined Chemotherapy Protocols*/pharmacokinetics , Antineoplastic Combined Chemotherapy Protocols*/economics , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage, Humans ; Male ; Models, Biological ; Female ; Middle Aged ; Aged ; Adult ; Dose-Response Relationship, Drug ; Indoles ; Pyrimidines

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC.

Autoren: Xu Y Zhang Y Jin H et al.

Quelle: Annals of medicine [Ann Med] 2025 Dec; Vol. 57 (1), pp. 2493766. Date of Electronic Publication: 2025 Apr 25.

Publikationsart: Journal Article; Comparative Study

Info zur Zeitschrift: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/mortality , Carcinoma, Non-Small-Cell Lung*/pathology , Bevacizumab*/administration & dosage , Bevacizumab*/therapeutic use , Acrylamides*/administration & dosage , Acrylamides*/therapeutic use , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/mortality , Lung Neoplasms*/pathology , Aniline Compounds*/administration & dosage , Aniline Compounds*/therapeutic use , Protein Kinase Inhibitors*/administration & dosage , Protein Kinase Inhibitors*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage, Humans ; Female ; Male ; ErbB Receptors/genetics ; ErbB Receptors/antagonists & inhibitors ; Middle Aged ; Aged ; Mutation ; Adult ; Retrospective Studies ; Treatment Outcome ; Progression-Free Survival ; Indoles ; Pyrimidines

Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study.

Autoren: Yang W Zhang J Wu G et al.

Quelle: Drug design, development and therapy [Drug Des Devel Ther] 2025 Nov 21; Vol. 19, pp. 10269-10280. Date of Electronic Publication: 2025 Nov 21 (Print Publication: 2025).

Publikationsart: Journal Article; Clinical Trial, Phase II; Case Reports; Clinical Trial

Info zur Zeitschrift: Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE

MeSH-Schlagworte: Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/metabolism , Receptor, ErbB-2*/antagonists & inhibitors , Receptor, ErbB-2*/metabolism , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Acrylamides*/administration & dosage , Acrylamides*/pharmacology , Trastuzumab*/administration & dosage , Trastuzumab*/pharmacology , Trastuzumab*/therapeutic use , Aminoquinolines*/administration & dosage , Aminoquinolines*/pharmacology, Humans ; Female ; Middle Aged ; Male ; Aged ; Adult ; Dose-Response Relationship, Drug

Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy.

Autoren: Cecere FL D'Argento E Gelsomino F et al.

Quelle: Clinical and experimental medicine [Clin Exp Med] 2025 Nov 18; Vol. 26 (1), pp. 18. Date of Electronic Publication: 2025 Nov 18.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 100973405 Publication Model: Electronic Cited Medium: Internet ISSN: 1591-9528 (Electronic) Linking ISSN: 15918890 NLM ISO Abbreviation: Clin Exp Med Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Acrylamides*/therapeutic use , Acrylamides*/administration & dosage , Proto-Oncogene Proteins c-met*/genetics , Proto-Oncogene Proteins c-met*/antagonists & inhibitors , Antineoplastic Agents*/therapeutic use, Humans ; Male ; Retrospective Studies ; Female ; Aged ; Italy ; Middle Aged ; Compassionate Use Trials ; Aged, 80 and over ; Adult ; Treatment Outcome ; Exons ; Protein Kinase Inhibitors/therapeutic use ; Benzamides ; Imidazoles ; Triazines

Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trial.

Autoren: Zhou H Lv M Li W et al.

Quelle: The oncologist [Oncologist] 2025 Nov 11; Vol. 30 (11).

Publikationsart: Journal Article; Clinical Trial, Phase II

Info zur Zeitschrift: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

MeSH-Schlagworte: Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/genetics , Aminoquinolines*/therapeutic use , Aminoquinolines*/pharmacology , Aminoquinolines*/adverse effects , Acrylamides*/therapeutic use , Acrylamides*/pharmacology , Acrylamides*/adverse effects , Neoplasms*/drug therapy , Neoplasms*/pathology , Neoplasms*/genetics, Humans ; Female ; Middle Aged ; Aged ; Adult ; Male ; Aged, 80 and over

The N6-methyladenosine-mediated cLMNB1 degrades FGFR4 to overcome osimertinib resistance in non-small cell lung cancer.

Autoren: Qian Y Wang H Feng Y et al.

Quelle: Cell death & disease [Cell Death Dis] 2025 Nov 10; Vol. 16 (1), pp. 818. Date of Electronic Publication: 2025 Nov 10.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE

MeSH-Schlagworte: Drug Resistance, Neoplasm*/drug effects , Drug Resistance, Neoplasm*/genetics , Acrylamides*/pharmacology , Acrylamides*/therapeutic use , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Lung Neoplasms*/metabolism , Adenosine*/analogs & derivatives , Adenosine*/metabolism , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/metabolism , Carcinoma, Non-Small-Cell Lung*/pathology , Aniline Compounds*/pharmacology , Aniline Compounds*/therapeutic use , Receptor, Fibroblast Growth Factor, Type 4*/metabolism , Receptor, Fibroblast Growth Factor, Type 4*/genetics, Humans ; Animals ; RNA, Circular/metabolism ; RNA, Circular/genetics ; Mice ; Cell Line, Tumor ; Mice, Nude ; Methyltransferases/metabolism ; Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/genetics ; Indoles ; Pyrimidines

Real-world study of first-line therapy with aumolertinib for elderly patients with non-small cell lung cancer harboring EGFR mutation.

Autoren: Liu N Xu S Xie Y et al.

Quelle: Medicine [Medicine (Baltimore)] 2025 Nov 07; Vol. 104 (45), pp. e45702.

Publikationsart: Journal Article; Observational Study

Info zur Zeitschrift: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/mortality , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/mortality , Acrylamides*/therapeutic use , Acrylamides*/adverse effects , Acrylamides*/administration & dosage , Antineoplastic Agents*/therapeutic use , Antineoplastic Agents*/adverse effects, Humans ; Aged ; Female ; Male ; ErbB Receptors/genetics ; Middle Aged ; Mutation ; Aged, 80 and over ; Aniline Compounds/therapeutic use ; Progression-Free Survival ; Age Factors ; Treatment Outcome ; Retrospective Studies ; Indoles ; Pyrimidines

ZDHHC11-mediated AXL palmitoylation promotes osimertinib resistance in non-small-cell lung cancer.

Autoren: Cui H Cai X Qian Q et al.

Quelle: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2025 Nov 04; Vol. 122 (44), pp. e2502778122. Date of Electronic Publication: 2025 Oct 28.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/metabolism , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/pathology , Acyltransferases*/metabolism , Acyltransferases*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/metabolism , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Proto-Oncogene Proteins*/metabolism , Proto-Oncogene Proteins*/genetics , Drug Resistance, Neoplasm*/drug effects , Acrylamides*/pharmacology , Acrylamides*/therapeutic use , Receptor Protein-Tyrosine Kinases*/metabolism , Receptor Protein-Tyrosine Kinases*/genetics , Aniline Compounds*/pharmacology , Aniline Compounds*/therapeutic use, Humans ; Lipoylation/drug effects ; Axl Receptor Tyrosine Kinase ; Animals ; Mice ; Cell Line, Tumor ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Signal Transduction/drug effects ; Indoles ; Pyrimidines

Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.

Autoren: Kodama H Murakami H Mamesaya N et al.

Quelle: Thoracic cancer [Thorac Cancer] 2025 Nov; Vol. 16 (22), pp. e70192.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley Publishing Asia Pty Ltd Country of Publication: Singapore NLM ID: 101531441 Publication Model: Print Cited Medium: Internet ISSN: 1759-7714 (Electronic) Linking ISSN: 17597706 NLM ISO Abbreviation: Thorac Cancer Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/genetics , Acrylamides*/therapeutic use , Acrylamides*/pharmacology , Aniline Compounds*/therapeutic use , Aniline Compounds*/pharmacology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/genetics , Mutation*, Humans ; Male ; Female ; Aged ; Middle Aged ; ErbB Receptors/genetics ; Retrospective Studies ; Aged, 80 and over ; Protein Kinase Inhibitors/therapeutic use ; Adult ; Disease Progression ; Indoles ; Pyrimidines

Population Pharmacokinetics and Exposure-Response Analysis of First-Line Osimertinib Plus Chemotherapy in Patients with EGFR-Mutated Advanced NSCLC.

Autoren: Yang J Olabode D Sawant-Basak A et al.

Quelle: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2025 Nov; Vol. 118 (5), pp. 1110-1121. Date of Electronic Publication: 2025 Jul 10.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE

MeSH-Schlagworte: Aniline Compounds*/pharmacokinetics , Aniline Compounds*/administration & dosage , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/pathology , Acrylamides*/pharmacokinetics , Acrylamides*/administration & dosage , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/pharmacokinetics , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; ErbB Receptors/genetics ; Female ; Male ; Mutation ; Middle Aged ; Aged ; Pemetrexed/administration & dosage ; Progression-Free Survival ; Adult ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Models, Biological ; Indoles ; Pyrimidines